merck hansoh news - Search News

Merck reaches weight-loss drug deal worth up to $2 billion

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.

UPI on MSN · 1d

Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes a $112 million licensing rights payment for global sales outside China.

YAHOO!Finance · 1d

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

Pharmabiz8m

Merck inks global license agreement with Hansoh Pharma for investigational oral GLP-1 receptor agonist

Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a leading pharmaceutical company in Greater China, announced that they have entered into an exclusive global license ...

Seeking Alpha on MSN1d

Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers

Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after ...

FierceBiotech1d

Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Yahoo Finance19h

MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results